Stemirna COVID-19 vaccine

Stemirna COVID-19 vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	mRNA
Clinical data
Other names	SW 0123
Routes of administration	Intramuscular
Identifiers
CAS Number	2699076-70-3^[1]

COVID-19 pandemic
Part of a series on the

COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society African diaspora Animals Alzheimer's disease patients Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBTQ community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal

Stemirna COVID-19 vaccine is a COVID-19 vaccine candidate developed by Stemirna Therapeutics.^[2]^[3] The Stemirna COVID-19 vaccine is labeled as a mRNA vaccine which means it causes the body to make a protein specific to the vaccine which triggers a immune response from the body.^[4] Stemirna first started the production of vaccines in result of the COVID-19 pandemic, therefore the first vaccine the began producing was a COVID-19 vaccine.^[5]

^ World Intellectual Property Organization. (2022). COVID-19-related vaccines and therapeutics: Preliminary insights on related patenting activity during the pandemic (PDF). Geneva: World Intellectual Property Organization. doi:10.34667/tind.45030. ISBN 978-92-805-3359-0.
^ "Randomized, double-blind, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of mRNACOVID-19 vaccine in healthy susceptible populations aged 18 years and older people". Chinese Clinical Trial Registry (ChiCTR). Archived from the original on 15 May 2021. Retrieved 15 May 2021.
^ Clinical trial number NCT05144139 for "A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above" at ClinicalTrials.gov
^ Yang R, Deng Y, Huang B, Huang L, Lin A, Li Y, et al. (31 May 2021). "A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity". Signal Transduction and Targeted Therapy. 6 (1): 213. doi:10.1038/s41392-021-00634-z. ISSN 2059-3635. PMC 8165147. PMID 34059617.
^ Taylor NP (4 June 2021). "China's Stemirna raises $188M to fund mRNA COVID-19 vaccine". www.fiercebiotech.com. Retrieved 28 April 2025.